Free Delivery Over $100
|
|
|||
|
||||
OverviewFull Product DetailsAuthor: Peter F. Thall (M.D. Anderson Cancer Center, Houston, Texas, USA)Publisher: Taylor & Francis Ltd Imprint: Chapman & Hall/CRC Weight: 0.770kg ISBN: 9781032754468ISBN 10: 103275446 Pages: 318 Publication Date: 07 May 2024 Audience: College/higher education , Professional and scholarly , Tertiary & Higher Education , Professional & Vocational Format: Hardback Publisher's Status: Forthcoming Availability: Not yet available  This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release. Table of ContentsReviews“With this latest book, Dr. Thall adds to his reputation as one of the most innovative thinkers in the field of adaptive clinical trial design. This book offers a wide variety of cutting-edge methods in Bayesian precision medicine, all explicated in the context of utility-driven designs that can simultaneously evaluate and trade off treatment safety and efficacy. The book’s unification of standard tools for causal inference with Bayesian methods is very welcome, as is its generous collection of case studies, most drawn from the author’s own extensive statistical consulting portfolio. It is a must-read for students and practitioners in biopharmaceutical statistics who want to see the current frontier of individualized complex innovative trial design.”~ Bradley P. Carlin, Cencora-PharmaLex, USA “With this latest book, Dr. Thall adds to his reputation as one of the most innovative thinkers in the field of adaptive clinical trial design. This book offers a wide variety of cutting-edge methods in Bayesian precision medicine, all explicated in the context of utility-driven designs that can simultaneously evaluate and trade off treatment safety and efficacy. The book’s unification of standard tools for causal inference with Bayesian methods is very welcome, as is its generous collection of case studies, most drawn from the author’s own extensive statistical consulting portfolio. It is a must-read for students and practitioners in biopharmaceutical statistics who want to see the current frontier of individualized complex innovative trial design.” Bradley P. Carlin, Cencora-PharmaLex, USA Author InformationPeter F. Thall is a global leader in the development and application of Bayesian methods in medical research, with over 300 publications in professional journals. His research interests include Bayesian statistics, clinical trial design, precision medicine, and dynamic treatment regimes. Tab Content 6Author Website:Countries AvailableAll regions |
||||
